2023 - Research.com Microbiology in France Leader Award
Her primary areas of study are Internal medicine, Immunology, Viral load, Acquired immunodeficiency syndrome and Virology. Her Internal medicine research includes elements of Gastroenterology and Darunavir. The Immunology study combines topics in areas such as Prospective cohort study and Risk factor.
Her Viral load research includes themes of Protease inhibitor, Pharmacotherapy and Combination therapy, Pharmacology. Her Acquired immunodeficiency syndrome research is multidisciplinary, relying on both Viral disease, Virus, Incidence and Cohort study. Her Virology study integrates concerns from other disciplines, such as Integrase inhibitor, Raltegravir, Cytotoxic T cell and Raltegravir Potassium.
Her primary scientific interests are in Virology, Internal medicine, Viral load, Immunology and Acquired immunodeficiency syndrome. Her Virology research integrates issues from Raltegravir, Drug resistance and Antigen. Her Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Darunavir, Surgery and Pharmacology.
The concepts of her Viral load study are interwoven with issues in Protease inhibitor, Pharmacotherapy, Ritonavir, Prospective cohort study and Emtricitabine. Her Immunology study frequently draws connections between adjacent fields such as Cytotoxic T cell. Many of her studies on Acquired immunodeficiency syndrome apply to Disease as well.
Christine Katlama spends much of her time researching Virology, Internal medicine, Viral load, Immunology and Regimen. Her Virology study combines topics in areas such as Mutation, Raltegravir, Reverse transcriptase and Genotype. Her work deals with themes such as Gastroenterology, Darunavir, Efavirenz, Ritonavir and Emtricitabine, which intersect with Internal medicine.
Her studies in Viral load integrate themes in fields like Odds ratio, Lamivudine, Lopinavir, Prospective cohort study and Cohort. Her Immunology research incorporates themes from Multiple drug resistance and Acquired immunodeficiency syndrome. Christine Katlama combines subjects such as Logistic regression and Pediatrics with her study of Acquired immunodeficiency syndrome.
Her scientific interests lie mostly in Internal medicine, Immunology, Virology, Viral load and Pharmacology. Her Internal medicine research includes themes of Gastroenterology, Surgery, Cross-sectional study and Emtricitabine. Her research in Immunology intersects with topics in Acquired immunodeficiency syndrome, Antiretroviral therapy and Homeostasis.
Her Viral replication study, which is part of a larger body of work in Virology, is frequently linked to Context, bridging the gap between disciplines. Her Viral load research incorporates elements of Regimen and Darunavir. The Pharmacology study combines topics in areas such as Atazanavir, Etravirine and Abacavir.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study
Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka.
PLOS ONE (2015)
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Y Benhamou;M Bochet;V Di Martino;F Charlotte.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
A Mocroft;B Ledergerber;C Katlama;O Kirk.
The Lancet (2003)
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi.
The Lancet (2004)
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron.
The New England Journal of Medicine (2008)
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
TS Li;R Tubiana;C Katlama;V Calvez.
The Lancet (1998)
AIDS across Europe, 1994–98: the EuroSIDA study
A Mocroft;C Katlama;AM Johnson;C Pradier.
The Lancet (2000)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh.
The New England Journal of Medicine (2008)
Towards an HIV cure: a global scientific strategy
Steven G Deeks;Brigitte Autran;Ben Berkhout;Monsef Benkirane.
Nature Reviews Immunology (2012)
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
Caroline Besson;Aicha Goubar;Jean Gabarre;Willy Rozenbaum.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: